- Home
- OTLY vs ATYR Comparison
OTLY vs ATYR Comparison
Compare OTLY & ATYR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OTLY
- ATYR
- Stock Information
- Founded
- OTLY 1994
- ATYR 2005
- Country
- OTLY Sweden
- ATYR United States
- Employees
- OTLY N/A
- ATYR N/A
- Industry
- OTLY Packaged Foods
- ATYR Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- OTLY Consumer Staples
- ATYR Health Care
- Exchange
- OTLY Nasdaq
- ATYR Nasdaq
- Market Cap
- OTLY 303.5M
- ATYR 306.2M
- IPO Year
- OTLY 2021
- ATYR 2015
- Fundamental
- Price
- OTLY $12.19
- ATYR $5.09
- Analyst Decision
- OTLY Buy
- ATYR Strong Buy
- Analyst Count
- OTLY 5
- ATYR 6
- Target Price
- OTLY $18.40
- ATYR $20.20
- AVG Volume (30 Days)
- OTLY 124.7K
- ATYR 3.4M
- Earning Date
- OTLY 07-23-2025
- ATYR 08-12-2025
- Dividend Yield
- OTLY N/A
- ATYR N/A
- EPS Growth
- OTLY N/A
- ATYR N/A
- EPS
- OTLY N/A
- ATYR N/A
- Revenue
- OTLY $822,041,000.00
- ATYR N/A
- Revenue This Year
- OTLY $4.31
- ATYR $960.85
- Revenue Next Year
- OTLY $5.01
- ATYR $1,283.47
- P/E Ratio
- OTLY N/A
- ATYR N/A
- Revenue Growth
- OTLY 4.47
- ATYR N/A
- 52 Week Low
- OTLY $6.00
- ATYR $1.48
- 52 Week High
- OTLY $23.40
- ATYR $5.98
- Technical
- Relative Strength Index (RSI)
- OTLY 54.80
- ATYR 55.16
- Support Level
- OTLY $11.84
- ATYR $4.78
- Resistance Level
- OTLY $13.26
- ATYR $5.50
- Average True Range (ATR)
- OTLY 0.70
- ATYR 0.37
- MACD
- OTLY -0.07
- ATYR -0.09
- Stochastic Oscillator
- OTLY 39.50
- ATYR 25.68
About OTLY Oatly Group AB
Oatly Group AB is engaged in the food and drinks industry. Some of its products include Oat Drink, Chilled Oat Drink, Oatgurt, Creamy Oat, and Icecreams, among others. It caters to Sweden, Germany, the United Kingdom, Netherlands, North America, Finland, and Other markets. The company generates revenue from the EMEA, Americas, and Asia regions, with the majority of revenue generated from the EMEA region.
About ATYR aTyr Pharma Inc. Common Stock
aTyr Pharma Inc is a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform. The company has concentrated its research and development efforts on a newly discovered area of biology, the extracellular functionality and signaling pathways of tRNA synthetases. Its primary focus is efzofitimod, a clinical-stage product candidate which targets NRP2 to resolve chronic inflammation that can cause to fibrosis. Efzofitimod has a novel mechanism of action for potentially treating lung inflammation and fibrosis.